Italia markets closed

Valneva SE (VLA.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
4,0160+0,0720 (+1,83%)
Alla chiusura: 05:35PM CEST
Schermo intero
Chiusura precedente3,9440
Aperto3,9780
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno3,9500 - 4,2640
Intervallo di 52 settimane2,9500 - 7,8460
Volume1.204.134
Media Volume529.157
Capitalizzazione558,838M
Beta (5 anni mensile)0,83
Rapporto PE (ttm)N/D
EPS (ttm)-0,7300
Prossima data utili07 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A9,40
  • GlobeNewswire

    Valneva to Present on Chikungunya at Several Leading Scientific Conferences

    Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023. At IDWeek, the annual meeting of the Infectious Diseases Society of America (IDSA), Valneva will support the roundtable discussion “Chikungunya is an Increasing Global Threat: The Need for Better Protection” taking place on Octo

  • GlobeNewswire

    VALNEVA - Declaration of shares and voting rights: September 30, 2023

    VALNEVA Declaration of shares and voting rightsSeptember 30, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: October 5, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change

  • GlobeNewswire

    Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

    Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Delive